Premium
P3‐012: Novel biomarkers for the differential diagnosis of Alzheimer's disease and vascular dementia
Author(s) -
Simonsen Anja H.,
Hagnelius NilsOlof,
Zhang Fujun,
Fung Eric,
Nilsson Torbjörn K.,
Waldemar Gunhild
Publication year - 2009
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2009.04.1189
Subject(s) - vascular dementia , dementia , differential diagnosis , medical diagnosis , disease , biomarker , medicine , chromogranin a , alzheimer's disease , pathology , oncology , biology , immunohistochemistry , genetics
Background: Alzheimer’s disease (AD) is the most common form of dementia found in all human populations worldwide, vascular dementia (VaD) is the second most common form of dementia. New biomarkers for early and specific diagnosis of AD and VaD are needed to achieve greater insight into changes occurring in the brain and direct therapeutic strategies. The objective of this study was to develop a multi-marker protein based test for early, differential diagnosis of AD and VaD that improves on the performance of current assays employing single biochemical markers. Methods: Dementia diagnoses and differential diagnoses were made using DSM-IV and ICD-10 criteria. Surface Enhanced Laser Desorption/Ionization (SELDI) TOF-MS was used to differentially profile proteins and peptides in CSF samples from 28 AD patients and 21 patients with VaD. Results: A total of 19 candidate biomarkers separating AD from VaD were found with ROC values above 0.7. Among them were two truncated forms of Ubiquitin (p1⁄4 0.0001) as well as Chromogranin B and Secretogranin V fragments (p1⁄4 0.0056 and p 1⁄4 0.0038, respectively). A multivariate model combining 5 peaks resulted in a ROC value of 0.835 Conclusions: This novel panel of biomarkers could potentially be used to improve early differential disease diagnosis of AD and VaD as well as provide complementary information to help decision making in the development of disease modifying compounds.